Cytek Biosciences reaffirms its 2024 revenue guidance, expecting full year 2024 revenue in the range of $203 million to $213 million, representing growth of 5% to 10% over full year 2023, assuming no change in currency exchange rates. For the year ending December 31, 2024, Cytek Biosciences expects to report positive net income.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.96 USD | +0.68% | -2.30% | -34.65% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.65% | 777M | |
+10.03% | 223B | |
+13.59% | 194B | |
+20.01% | 141B | |
+30.83% | 109B | |
+2.05% | 64.85B | |
+15.38% | 52.7B | |
+3.96% | 51.77B | |
+8.37% | 44.12B | |
+3.27% | 36.21B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024